TactoTek Welcomes Dr. Pälvi Apilo as New Chief Technology Officer
April 4, 2025 - 13:41
In a strategic move to enhance its technological capabilities, TactoTek has appointed Dr. Pälvi Apilo as the new Chief Technology Officer. Dr. Apilo brings a wealth of experience and expertise in advanced manufacturing and materials science, which will be pivotal as the company seeks to advance its innovative In-Mold Structural Electronics (IMSE) technology.
With her leadership, TactoTek aims to further streamline its manufacturing processes and reduce material usage, aligning with global sustainability goals. Dr. Apilo's background includes significant contributions to research and development in the fields of polymers and electronics, making her an ideal fit for the role.
The company is optimistic that her appointment will accelerate the development of cutting-edge solutions that integrate electronics into molded parts, ultimately simplifying production and enhancing product design. TactoTek is committed to pushing the boundaries of technology, and Dr. Apilo's expertise is expected to play a crucial role in this mission.
MORE NEWS
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...